Skip to main content

Table 5 PROGRESS comorbidities

From: The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes

Variable DrotAA
n = 882
Non-DrotAA
n = 11,610
Total
n = 12,492
P value
Diabetes, n (%) (n = 766)
164 (21.4)
(n = 10,352)
2441 (23.6)
(n = 11,118)
2605 (23.4)
0.17
Chronic lung disease, n (%) (n = 870)
136 (15.6)
(n = 11,447)
1924 (16.8)
(n = 12,317)
2060 (16.7)
0.37
Active cancer, n (%) (n = 844)
102 (12.1)
(n = 11,101)
1787 (16.1)
(n = 11,945)
1889 (15.8)
0.002
Congestive heart failure, n (%) (n = 879)
97 (11.0)
(n = 11,460)
1630 (14.2)
(n = 12,339)
1727 (14.0)
0.009
Chronic renal insufficiency, n (%) (n = 872)
54 (6.2)
(n = 11,481)
1285 (11.2)
(n = 12,353)
1339 (10.8)
<0.001
Chronic liver disease, n (%) (n = 843)
48 (5.7)
(n = 11,142)
727 (6.5)
(n = 11,985)
775 (6.5)
0.34
Other, n (%) (n = 768)
197 (25.7)
(n = 10,369)
2473 (23.9)
(n = 11,125)
2670 (24.0)
0.90
  1. DrotAA = drotrecogin alfa (activated); PROGRESS = Promoting Global Research Excellence in Severe Sepsis.